The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Mar. 29, 11:34 AM

Slide #14. Aquestive Therapeutics, Inc. Secondary Offering

Company: Aquestive Therapeutics, Inc. (NASDAQ:AQST)
Date announced: 3/19/2024
Shares Offered: 16,666,667
Date of Pricing: 3/19/2024
Price Per Share: $4.50
Secondary Offering Details: Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. All of the securities in the public offering are being offered by Aquestive. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 3/19- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be approximately $75.0 million. The Company intends to use the net proceeds received from the offering, together with the Company's existing cash and cash equivalents, primarily to advance the development and commercialization of its product pipeline, including Anaphylm (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, and Libervant (diazepam) Buccal Film for the treatment of seizure clusters in epilepsy patients aged two to five, and for working capital, capital expenditures and general corporate purposes. In addition, Aquestive has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are to be sold by the Company. The offering is expected to close on or about March 22, 2024, subject to satisfaction of customary closing conditions.

Aquestive Therapeutics is a pharmaceutical company. Co. is improving medicines to solve patients' problems with care and provide transformative products to improve their lives. Co. is developing pharmaceutical products that deliver molecules through alternative administrations to invasive and inconvenient standard of care therapies. Co. also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, like PharmFilm®. Co. is developing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. Co. has also developed a product pipeline focused on treating diseases of the central nervous system (CNS).
Open the AQST Page at The Online Investor »

Company Name:  Aquestive Therapeutics Inc
Website:  www.aquestive.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding AQST:  3
Total Market Value Held by ETFs:  $10.48M
Total Market Capitalization:  $301.00M
% of Market Cap. Held by ETFs:  3.48%
 

Open the AQST Page at The Online Investor (in a new window) »

March 29, 2024    11:34 AM Eastern
Quotes delayed 20 minutes

Email EnvelopeFree AQST Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.83 out of 4)
73rd percentile
(ranked higher than approx. 73% of all stocks covered)

Analysts' Target Price:
AQST Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.